The Role of Biologics Agent in the Treatment of Inflammatory Bowel Disease
Abstract: Inflammatory bowel
disease (IBD), with major manifestations as Crohn’s disease (CD) and ulcerative
colitis (UC), is a chronic intestinal inflammatory disorder with an unknown
etiology which pathogensis involving multifactorial immune disorder characterized
by chronic relapsing inflammation of the intestine. Management of IBD depends
on stage and location of the inflammation consist of the classic conventional
treatment and the more new treatment with biologics agent. Biologics agent
refers to monoclonal antibodies with activity directed against specific targets
involved in the pathogenesis of chronic inflammatory conditions. Advances in
the understanding of the specific mechanisms of pathogenesis IBD led to the
development of targeted treatment. Today there are six biologics agent approved
and used as therapy and there still many other biologics agent on research
progress. Many reports show positive report about efficacy for the biological
therapy compared with placebo and conventional treatment for the IBD. Limited
by their cost and adverse effect that possibly happened, biologics agent is
still promising therapy that change the course of IBD treatment.
Keyword: Inflammatory bowel
disease (IBD); Crohn’s disease (CD); ulcerative colitis (UC); biological therapy;
biologics agent
Author: Tri Hapsoro Guno,
Marcellus Simadibrata
Journal Code: jpkedokterangg170395
